Zhong Lun Law Firm and O’Melveny & Myers have advised Chinese drug development service provider Pharmaron on its $588 million Hong Kong initial public offering, with JunHe and Skadden, Arps, Slate, Meagher & Flom advising the joint sponsors.

According to a press release, Pharmaron, based in Beijing and founded in 2004, is a fully integrated pharmaceutical Research & Development platform serving China and overseas pharmaceutical companies, assisting on drug discovery, pre-clinical and early clinical-stage development, while also expanding capabilities downstream to late clinical-stage development and commercial manufacturing.

The Zhong Lun team was led by partners Hu Tingfeng and Wang Chuan; the OMM team was led by partners Portia Ku, Zhu Ke and Edwin Kwok; the JunHe team was led by partner Wang Yi, with assistance from partner Sun Xiaojia; and the Skadden team was led by partners Julie Gao and Paloma Wang.

The Joint Sponsors are Goldman Sachs, CLSA and Orient Capital.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

CC, Paul Hastings lead on CR Beverages’ HK IPO

by Charlie Wu 吴卓言 |

Clifford Chance and Jingtian & Gongcheng are advising China Resources Beverages, the beverage division of the state-owned China Resources Enterprise, on its upcoming Hong Kong IPO, which is expected to raise up to $1 billion. Paul Hastings and Zhong Lun Law Firm are acting for the joint sponsors.

Other News

PRC’s East IP, HK’s SIPS merge, add Zhong Lun IP team

by Hu Yangxiaoxiao 胡阳潇潇 |

PRC IP firm Beijing East IP has merged with the Hong Kong-headquartered SIPS, and also welcomed aboard a team of 36 IP professionals from Zhong Lun Law Firm.

Deals

Davis Polk, Zhong Lun guiding Mixue’s billion-dollar HK IPO

by Mari Iwata |

Davis Polk & Wardwell and Zhong Lun Law Firm are advising China's largest bubble-tea chain store, Mixue Bingcheng, on its IPO on the Hong Kong Stock Exchange, which aims to raise between $500 million and $1 billion.